{"id":78346,"date":"2026-06-05T17:49:11","date_gmt":"2026-06-05T17:49:11","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/78346\/"},"modified":"2026-06-05T17:49:11","modified_gmt":"2026-06-05T17:49:11","slug":"nestle-and-helaina-enter-partnership-in-infant-nutrition-space","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/78346\/","title":{"rendered":"Nestl\u00e9 and Helaina enter partnership in infant nutrition space"},"content":{"rendered":"

Nestl\u00e9\u2019s new partnership <\/a>with biotech startup Helaina signals a deeper push into next-generation ingredients that bring infant formula closer to the composition of human breast milk \u2013 a long-standing goal across the category.<\/p>\n

While details on specific product applications remain under wraps, Helaina founder and CEO Laura Katz said the collaboration is primarily focused on early-life nutrition.<\/p>\n

At the center of the partnership is lactoferrin, a bioactive protein that plays a critical role in infant health and is one of the most abundant functional proteins in human breast milk<\/a>. Historically, the ingredient has been difficult to scale, produced only in small quantities from cow\u2019s milk and subject to supply and pricing fluctuations.<\/p>\n

Helaina uses precision fermentation to produce what it describes as a human-identical version of lactoferrin, marketed as effera. According to Katz, precision fermentation offers functional and supply chain advantages over traditional sources.<\/p>\n

Effera\u2019s stable production could be meaningful for large formula manufacturers when ingredient price swings complicate formulation and long-term planning. Katz noted that bovine lactoferrin prices can \u201cchange dramatically\u201d by \u201chundreds of dollars a kilo,\u201d making consistency a key unlock for broader adoption.<\/p>\n

\u201cThe whole industry of infant formula is working to move towards as close as possible \u2026 to breast milk,\u201d she added. <\/p>\n

\u2018We did the fats, we did the sugars, now it\u2019s the proteins\u2019<\/p>\n

The partnership also helps normalize the use of biotechnologies in formula, Katz said.<\/p>\n

Bioactive proteins are the next frontier, she said, adding: \u201cWe did the fats, we did the sugars, now it\u2019s the proteins.\u201d <\/p>\n

Infant formula makers have been steadily layering in bioactive-enabled ingredients \u2013 first fats, like omega-3s, then human milk oligosaccharides (HMOs) \u2013 to more closely replicate breast milk. <\/p>\n

The progression of tech and ingredient production, coupled with growing clinical and commercial precedent, may ease concerns around consumer acceptance of such technologies, Katz said.<\/p>\n

Helaina\u2019s expertise in bioactive proteins and its ability to scale volumes to meet Nestl\u00e9\u2019s infant nutrition needs is the next step in that evolution.<\/p>\n

\u201cOur goal as a company is to bring human bioactives to every baby and adult in the world,\u201d Katz emphasized.<\/p>\n

Building credibility and efficacy \u2018in public\u2019<\/p>\n

The partnership also reflects a shared emphasis on scientific research and commitment to safety. Helaina has taken an intentionally transparent approach, publishing roughly a dozen scientific papers on its technology.<\/p>\n

\u201cWe\u2019ve basically built in public,\u201d Katz said.<\/p>\n

That research-first mindset made Nestl\u00e9 a natural partner, she added, pointing to the food giant\u2019s long-standing investment in nutrition science and ongoing research programs.<\/p>\n

\u201cHaving somebody who really has the same vision as we do, as well as the same commitment to research, is really important,\u201d Katz said.<\/p>\n

Navigating regulatory pathways on a global scale<\/p>\n

Still, bringing new ingredients into infant formula is as much about regulatory navigation as it is about R&D. Requirements vary significantly by region, particularly when it comes to clinical trials.<\/p>\n

\u201cDepending on where you go in the world, some regions require any new infant formula to go through a clinical trial. Some regions don\u2019t,\u201d Katz said.<\/p>\n

As a result, commercialization timelines and distribution strategies will depend heavily on geography.<\/p>\n

Helaina has already secured GRAs status for effera in the US, while its European expansion is still in progress, Katz said.<\/p>\n

The company is also pursuing approvals in other major markets, with regulatory strategy serving as a leading factor in where products can launch, she added.<\/p>\n

Delivering effera at scale<\/p>\n

Like many startups, execution at scale is one of the biggest hurdles to meet global demand. Helaina says it has achieved lactoferrin production at large volumes through fermentation, a milestone Katz describes as foundational.<\/p>\n

She said Helaina is producing metric tons of the protein today and has built the capability to scale further, positioning it to potentially become one of the largest lactoferrin producers globally.<\/p>\n

Ultimately, the partnership reflects a dual priority shaping the infant formula industry: Maintaining rigorous safety and regulatory standards while continuing to innovate on a consistent supply of bioactives. These priorities are particularly urgent given recent formula recalls<\/a> across CPG \u2013 from multinationals like Nestl\u00e9 and Danone to smaller US brands like ByHeart<\/a>.<\/p>\n

\u201cWe need to make sure \u2026 our formula supply is safe, and we also need it to advance and make it closer to breast milk,\u201d Katz said. \u201cIt\u2019s not an \u2018or,\u2019 it\u2019s an \u2018and.\u2019\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Nestl\u00e9\u2019s new partnership with biotech startup Helaina signals a deeper push into next-generation ingredients that bring infant formula…\n","protected":false},"author":2,"featured_media":78347,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[126],"tags":[28161,3099,2219,40852,40853,40854,3039,1169,40855,1002,2397,8839,417,2398,40856,1053,2401,21083,40857,34682,40858,199,1135,6029,26662,7207,630,40859,29195],"class_list":["post-78346","post","type-post","status-publish","format-standard","has-post-thumbnail","category-nestle","tag-accessories","tag-asian","tag-baby","tag-breastfeed","tag-business-mom-and-child","tag-feed","tag-female","tag-formula","tag-girl","tag-health","tag-healthy","tag-home","tag-infant","tag-kid","tag-lactation","tag-lifestyle","tag-little","tag-love","tag-maternity","tag-mom","tag-motherhood","tag-nestle","tag-nutrition","tag-stay","tag-together","tag-woman","tag-work","tag-work-from-home","tag-young"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116698766571766021","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/78346","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=78346"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/78346\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/78347"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=78346"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=78346"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=78346"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}